NAPA Federal Research Subgroup
|
Committee, Advisory Group, or Work Group
|
AHRQ, ASPE, ACL, CDC, CMS, FDA, HRSA, IHS
|
NIA, NINDS
|
|
|
NASEM Aging Disability and Independence Forum
|
Committee, Advisory Group, or Work Group
|
ACL
|
NIA
|
2014
|
|
National Academies Addressing Evidence Gaps in Clinical Prevention (NAM Evidence Gaps project)
|
Committee, Advisory Group, or Work Group
|
AHRQ
|
ODP
|
2020
|
|
National Academy of Medicine Committee on Emerging Science, Technology, and Innovation in Health and Medicine
|
Committee, Advisory Group, or Work Group
|
FDA
|
NIMH
|
2020
|
|
National Action Alliance for Suicide Prevention (NAASP)
|
Committee, Advisory Group, or Work Group
|
ACL, CDC, HRSA, IHS, OS, OSG, SAMHSA
|
NIAAA, NIDA, NIMH, OD/ DPCPSI/ OBSSR, ODP
|
2010
|
|
National Action Plan for Combating Antoibiotic-Resistant Bacteria (CARB) 2020-2025
|
Committee, Advisory Group, or Work Group
|
AHRQ, BARDA, CDC, CMS, FDA, HRSA, OS
|
NIAID
|
2019
|
|
National Advisory Board for Medical Rehabilitation Research
|
Committee, Advisory Group, or Work Group
|
ACL, CDC
|
NHLBI, NIA, NIAMS, NICHD, NIDCD, NINDS, OD/ DPCPSI
|
1991
|
|
National Advisory Committee on Children and Disasters (NAACD)
|
Committee, Advisory Group, or Work Group
|
CDC, FDA, HRSA, ASPR
|
NICHD, NIEHS
|
|
|
National Cancer Institute and HRSA Office of Women’s Health
Cervical Cancer Moonshot Roundtable Series:
Creating Capacity to Reduce Systems Barriers in Rural and Underserved Settings
|
Committee, Advisory Group, or Work Group
|
OASH, HRSA
|
NCI
|
2020
|
|
National Clinical Care Commission (NCCC)
|
Committee, Advisory Group, or Work Group
|
AHRQ, CDC, CMS, FDA, HRSA, IHS
|
NIDDK
|
2018
|
|
National Coalition for Oversite of Assisted Reproductive Technologies (NCOART)
|
Committee, Advisory Group, or Work Group
|
CDC, FDA
|
NICHD
|
1997
|
|
National Death Index Working Group
|
Committee, Advisory Group, or Work Group
|
CDC
|
CC, NCATS, NCI, NHLBI, NIA, NIAID, NIDA, NICHD, NIMH, OD/ DPCPSI/ OBSSR
|
2018
|
|
National Healthcare Quality and Disparities (NHQDR) Inter-Agency Workgroup
|
Committee, Advisory Group, or Work Group
|
AHRQ, CDC, CMS, HRSA
|
NCI, NIAID, NIEHS, NIMHD
|
2004
|
|
National Institutes of Health (NIH) Flow Cytometry Interest Group
|
Committee, Advisory Group, or Work Group
|
FDA
|
CC, NCI, NEI, NHLBI, NIAID, NIAMS, NIDCR
|
2005
|
|
National Institutes of Health (NIH) Metabolomics Scientific Interest Group
|
Committee, Advisory Group, or Work Group
|
FDA
|
NCI, NHLBI, NIA, NIAAA, NIAID, NIDCR, NIDDK, NIEHS, NIMH, NLM, OD/ DPCPSI/ ODS
|
2007
|
|
National Interagency Confederation for Biological Research
|
Committee, Advisory Group, or Work Group
|
CDC, FDA
|
, NIAID, NCI
|
2002
|
|
National Science Advisory Board for Biosecurity
|
Committee, Advisory Group, or Work Group
|
CDC, FDA, OS
|
NIAID, OD/ OSP
|
2004
|
|
National Science and Technology Council Subcommittee on Open Science (NSTC SOS)
|
Committee, Advisory Group, or Work Group
|
ACL, AHRQ, ASPR, CDC, FDA
|
NLM, OD/ OSP, OD/ OER
|
|
|
National Security Staff Dual Use Research of Concern Interagency Policy Committee (NSS DURC PCC)
|
Committee, Advisory Group, or Work Group
|
CDC, OS
|
NIAID, OD/ OSP
|
|
|
National Security Staff Dual Use Research of Concern Sub-Interagency Policy Committee (NSS DURC Sub-PCC)
|
Committee, Advisory Group, or Work Group
|
CDC, OS
|
NIAID, OD/ OSP
|
|
|
National Sexually Transmitted Infections (STI) Strategic Plan
|
Committee, Advisory Group, or Work Group
|
OASH, ACF, ACL, CDC, CMS, FDA, HRSA, IHS, SAMHSA
|
NIAID
|
2020
|
|
NCI Cancer Data Standards Repository and Registry (caDSR)
|
Committee, Advisory Group, or Work Group
|
FDA
|
CIT, NCI, NEI, NHLBI, NIAMS, NIBIB, NICHD, NIMH, NINDS, NLM, NCATS
|
2003
|
|
NCI Clinical Trials and Translational Research Advisory Committee (CTAC)
|
Committee, Advisory Group, or Work Group
|
CMS, FDA
|
NCI
|
2007
|
|
NCI's Surveillance, Epidemiology and End Results (SEER) cancer registry data and the Centers for Medicare & Medicaid Services' (CMS) Medicare Consumer Assessment of Healthcare Providers and Systems (CAHPS®) patient surveys.
|
Committee, Advisory Group, or Work Group
|
CMS
|
NCI
|
2013
|
|
NCI/FDA/HRSA/CMS Task Force on Cancer Diagnostic Devices (CD2) for Near-Patient Use
|
Committee, Advisory Group, or Work Group
|
CMS, FDA, HRSA
|
NCI
|
2019
|
|
|